Anzeige
Mehr »
Donnerstag, 15.01.2026 - Börsentäglich über 12.000 News
Diese Goldaktie beschleunigt ihr Explorationsprogramm - Ergebnisse sprengen den Plan
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2H48J | ISIN: SE0009973563 | Ticker-Symbol: 6XP
Frankfurt
15.01.26 | 09:55
2,680 Euro
-0,74 % -0,020
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
XSPRAY PHARMA AB Chart 1 Jahr
5-Tage-Chart
XSPRAY PHARMA AB 5-Tage-Chart
RealtimeGeldBriefZeit
2,3552,36515:38

Aktueller Chart XSPRAY PHARMA Aktie

Chart vergleichen mit:

Firmenname, WKN, ISIN oder Aktien-Kürzel

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%
Chart-Typ:
Zeitraum:
 
XSPRAY PHARMA AB-Investoren interessieren sich auch für diese Wertpapiere
Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional SharesWALTHAM, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven...
► Artikel lesen
Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Positive Topline Results from Phase 1/2 DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD)- Registrational Expansion Cohort (REC) met primary endpoint, demonstrating statistically significant increase in dystrophin to 5.46% at 6 months (muscle content-adjusted; p - Functional improvement...
► Artikel lesen
Dyne Therapeutics, Inc.: Dyne Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights- Topline data from Registrational Expansion Cohort of DELIVER trial of zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251) in DMD on track for December 2025 to support potential submission...
► Artikel lesen
Recursion Pharmaceuticals, Inc.: Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 WeeksREC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12)After 12 weeks...
► Artikel lesen
Recursion Pharmaceuticals: Recursion Reports Third Quarter 2025 Financial Results and Provides Business UpdateAchieved $30 million milestone from Roche and Genentech for delivering a whole-genome map of microglial immune cells-the second neuro map designed to accelerate treatments for a wide range of neurological...
► Artikel lesen
Recursion Pharmaceuticals: Recursion Announces CEO Transition Plan to Drive Next Phase of GrowthSalt Lake City, Utah, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that its Board...
► Artikel lesen